Studies of serum-free culture medium in the generation of lymphokine activated killer cells

Linda Mesler Muul, Kathryn Nason-Burchenal, Cornelia Hyatt, Susan Schwarz, Dale Slavin, Elaine P. Director, Steven A. Rosenberg

Research output: Contribution to journalArticlepeer-review

Abstract

Lymphokine activated killer (LAK) cells administered in conjunction with recombinant interleukin-2 can mediate the regression of metastatic tumor in some patients with advanced cancer. In these trials LAK cells were activated in medium containing 2% human type A or AB serum. We have found three commercially available, serum-free culture media which allow development of in vitro LAK activity by human peripheral blood lymphocytes. They are AIMV (Gibco), MASF-3 (Whitaker-MA Bioproducts) and HB-104 (Dupont). If 2-mercaptoethanol was added to these culture media they were also capable of generating murine LAK cells which were effective in reducing pulmonary metastases in the murine MCA-106 model. Although LAK cells generated in these media have not been tested in humans yet, potentially they could provide a safe, unlimited and less expensive source of culture fluid for generating the large numbers of LAK cells needed for human clinical trials.

Original languageEnglish (US)
Pages (from-to)183-192
Number of pages10
JournalJournal of Immunological Methods
Volume105
Issue number2
DOIs
StatePublished - Dec 24 1987

Keywords

  • Immunotherapy, adoptive
  • Interleukin-2, recombinant
  • Lymphokine-activated killer cell
  • Serum-free culture medium

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Fingerprint

Dive into the research topics of 'Studies of serum-free culture medium in the generation of lymphokine activated killer cells'. Together they form a unique fingerprint.

Cite this